Maureen shares how Actuated Medical grew from a focus on improving patient outcomes through innovative motion into a company with more than $50 million in non-dilutive funding, 43 patents, 9 FDA 510(k) clearances, and FDA-registered, ISO 13485-certified manufacturing infrastructure.

Rich and Maureen also discuss the TubeClear system, Actuated Medical's first FDA-cleared device, including the story of the first patient it helped at Walter Reed, and how that experience shaped the company's mission.

The episode also explores NeuralGlider® Precision Brain Access and Deep Brain Therapy Delivery Platform, including how earlier work in tissue penetration led to brain implant technology, DARPA-supported commercialization, global research use, and the company's next steps toward clinical applications.

Maureen also shares what comes next for Actuated Medical, including its focus on NeuroGlider, upcoming visibility at the MedTech Conference in Boston, and her advice to entrepreneurs building medical device companies: persistence matters.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Maureen L. Mulvihill, Ph.D., is Founder, President, and CEO of Actuated Medical, a medical device company advancing the NeuralGlider® Precision Brain Access and Deep Brain Therapy Delivery Platform for neurotechnology, brain therapeutics, and longevity-related medicine. Under her leadership, Actuated Medical has secured more than $50 million in non-dilutive funding, developed a portfolio of 43 patents, achieved 9 FDA 510(k) clearances, and earned two SBA Tibbetts Awards recognizing excellence in commercialization. Dr. Mulvihill serves on the Board of Directors of AdvaMed, the AdvaMed Accel Board, the Life Sciences Pennsylvania Board of Directors, chairs the Industrial Advisory Board for the Penn State Center for Biodevices, and serves on the Kish Bank Regional Advisory Board. She has received more than 35 entrepreneurship and leadership awards, including being named 2020 Life Sciences Pennsylvania CEO of the Year and leading Actuated Medical to First Place in the 2026 BioHealth Capital Region Crab Trap Competition. She earned her Ph.D. from The Pennsylvania State University.

Ralf introduces BioM, the organization supporting biotech development in Munich and Bavaria for nearly 30 years, and shares how the cluster helps founders move from research ideas to company formation. The conversation touches on mentoring, boot camps, investor connections, entrepreneur-in-residence support, startup training, and physical incubation.

Rich and Ralf also discuss the MAxL incubator, the m4 Award, and BioM's work with more than 250 startups. Ralf shares his perspective on what early-stage teams need most, why strong science alone is not enough, and how business leadership, IP, financing, market need, and the right commercialization path all play a role.

The episode also explores emerging opportunities in biotech and medicine, including AI, digital medicine, quantum computing, nanotechnology, regenerative medicine, tech bio, and the growing convergence of biology, engineering, and advanced technologies. Ralf also discusses why international collaboration matters for regional biotech clusters and how Bavarian companies are thinking about U.S. partnerships, investors, market access, and connections to ecosystems like the BioHealth Capital Region.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Ralf Huss, MD, PhD, is a physician-scientist, surgical pathologist, biotechnology executive, entrepreneur, and innovation leader with more than three decades of experience across academia, pharmaceutical research, biotechnology, digital pathology, regenerative medicine, and artificial intelligence in healthcare. He currently serves as Managing Director and CEO of BioM, the organization responsible for the development of the Bavarian Biotechnology Cluster, one of Europe's leading life science ecosystems. Throughout his career, he has held leadership positions in multinational pharmaceutical companies, venture-backed biotechnology firms, international academic research and medical centers, and innovation organizations, with a particular focus on translational medicine, cell and gene therapy, digital medicine, and AI-driven diagnostics. He has been awarded numerous honors and published more than 180 peer-reviewed articles, books, and book chapters.

Matt shares how BrainScope is using EEG-based technology and artificial intelligence to help decode brain electrical activity and provide clinicians, patients, and care teams with simple, actionable information. He explains why objective data is especially important in brain health, where many assessments can still be subjective, difficult to scale, or dependent on more expensive infrastructure.

The conversation also looks at BrainScope's evolution since winning the BioHealth Capital Region Crab Trap Competition in 2020. Matt discusses how the company has moved from a point-of-care EEG technology focused on traumatic brain injury into a broader AI-enabled brain health platform with potential applications across concussion, brain bleeds, dementia, Alzheimer's disease, and other neurological conditions.

Rich and Matt also discuss BrainScope's FDA-cleared technology, its growing clinical and regulatory foundation, and how the company is using machine learning, deep learning, and a large EEG database to expand what can be measured in brain health. Matt highlights the company's work in Alzheimer's prediction, including data suggesting the potential to identify risk years before typical clinical diagnosis, as well as the opportunity to support longitudinal monitoring and improved CNS trial design.

The episode also looks ahead to BrainScope's next phase, including expanded disease applications, partnerships with clinicians and sports medicine organizations, potential use in clinical trials, global market opportunities, and the company's continued growth in the BioHealth Capital Region.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Matt Adams brings more than 25 years of global healthcare leadership experience developing, commercializing, and scaling medical device, biotechnology, diagnostic product, and service businesses. He currently serves as Chief Executive Officer of BrainScope, a tech-enabled AI software platform focused on brain health. Before joining BrainScope, Matt was President of Invio Automation, a global life science-focused process automation provider. He previously served as Vice President and General Manager of Cerevention, a neuro startup that developed and commercialized platforms to diagnose and treat hemorrhagic stroke and other diseases of the central nervous system. He has also held executive roles at Rebiotix, Cirle, and American Medical Systems. Matt received his eMBA from the University of Minnesota, a Master of Science in Biomedical Engineering from the University of Minnesota, and a Bachelor of Science in Mechanical Engineering from the University of Alaska.

Sara shares how her career moved from life science operating companies to NIH and now to J.P. Morgan, where she works with early-stage life science and healthcare ventures across the DMV and surrounding regions. Drawing on her experience inside startups, supporting SBIR-funded companies, and advising founders from the business side, Sara brings a practical perspective on what early-stage teams need as they begin raising institutional capital and building the systems behind a company.

The conversation explores how J.P. Morgan supports companies across the full lifecycle, from inception through IPO and beyond. Sara also discusses the importance of secure banking infrastructure, investor readiness, cap table management, startup-focused resources, and relationship-building in a market where founders are often asked to do more with limited time and capital.

Rich and Sara also revisit her time at NIH, her work with BHI Entrepreneurs-in-Residence, and the value of the BioHealth Capital Region ecosystem in helping entrepreneurs connect with the right advisors, funders, and partners.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Sara Dauber is Vice President, J.P. Morgan's Startup Banking team, where she works with early-stage life science and healthcare companies in the DMV and broader Mid Atlantic. Before joining J.P. Morgan, Sara spent more than 14 years in life science operating companies, often working with early-stage startups across finance, program management, corporate development, business development, and operations. She later worked with NINDS at NIH, supporting SBIR-funded companies with business support. Today, she brings that experience to her work with founders as they build, finance, and scale life science and healthcare companies.

Jeff and Darryl explain how BioFactura's experience building biologics development and clinical manufacturing capabilities created the foundation for a more personalized CDMO model. The discussion explores the gap Capitol Biologics is designed to fill for emerging biotech companies that need integrated development support, scientific depth, analytical expertise, phase-appropriate quality, and early GMP manufacturing without being pushed into a large commercial-scale CDMO model too soon.

The conversation also highlights what biotech CEOs and CMC leaders should consider before choosing a CDMO partner, including developability assessment, cell line and process development, analytical characterization, quality systems, cost of goods, regulatory readiness, and timing. Jeff and Darryl also discuss the growing importance of U.S.-based biologics development and manufacturing capacity, especially for emerging biotech and government-aligned programs.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Jeffrey N. Hausfeld, M.D., M.B.A., F.A.C.S., is a physician entrepreneur, biotechnology executive, investor, and healthcare innovator whose career spans clinical medicine, life sciences, healthcare real estate development, and entrepreneurial leadership. A graduate of Yale University School of Medicine and recipient of an M.B.A. from Johns Hopkins University, Dr. Hausfeld is an Associate Clinical Professor of Surgery at George Washington University and has been actively involved in national medical societies and healthcare leadership organizations for more than four decades. He currently serves as Chairman of the Board and Chief Medical Officer of BioFactura Inc., Chairman of Capitol Biologics, and Chairman and Co-Founder of the Society of Physician Entrepreneurs. His work focuses on advancing healthcare innovation, biotechnology commercialization, physician entrepreneurship, and the responsible adoption of emerging technologies that improve patient care.

Darryl Sampey, Ph.D., is a biopharmaceutical executive and company builder with more than 30 years of experience advancing biologics from discovery through clinical development and commercial manufacturing. He co-founded BioFactura in 2004 and has guided the company from start-up through incubator stages into a fully integrated biopharmaceutical product development and clinical manufacturing company. At BioFactura, he has raised more than $90 million in non-dilutive and strategic funding, built cGMP manufacturing capabilities, and led development of novel therapeutics, biodefense medical countermeasures, biosimilars, and cell therapies. Dr. Sampey is an inventor of the VeriCyte™ Discovery and StableFast™ Biomanufacturing Platforms and previously held process development and manufacturing leadership roles at Human Genome Sciences and North American Vaccine.

A past winner of the BioHealth Capital Region Crab Trap Competition, Neal first joined BioTalk to discuss the deeply personal story behind the company. His family's experience during his son Noah's cancer treatment revealed the daily challenges of tube feeding, from limited mobility and caregiver burden to the lack of real-time data once patients leave the hospital.

Now, after six years of development, persistence, regulatory work, and product refinement, Luminoah is preparing to bring its portable, connected enteral nutrition system to patients, caregivers, clinicians, and health systems. Neal discusses what FDA clearance means for the company, how Luminoah Flow is designed to support more independence in daily life, and what comes next as the team prepares for early access programs, commercial rollout, and continued growth in the BioHealth Capital Region.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Neal Piper has devoted his career to advancing healthcare and expanding access to life-saving innovation across the U.S., Africa, and Asia. He began in Pfizer's Neuroscience Division before joining the Global Health Fellows Program, later serving as President of its Alumni Business Network, where he united 350 leaders and scientists to strengthen healthcare systems worldwide. He went on to expand healthcare programs in 18 countries with Population Services International and founded multiple ventures, including a home healthcare company. As the founding CEO of the Presidential Precinct, he empowered emerging and world leaders driving change in government, entrepreneurship, and civil society. Guided by a belief in the power of innovation to improve lives, Neal now leads Luminoah with a mission to create meaningful, lasting change in healthcare.

Jared shares how his experience in Louisiana and Nevada shaped his approach to economic development, including the importance of diversification, business retention, workforce strategy, and bringing partners together around shared goals. He also explains MCEDC's role as a public-private partnership and how the organization works with local government, chambers, business leaders, nonprofits, academic institutions, and other stakeholders to support companies across Montgomery County.

The discussion highlights the county's deep talent base, global diversity, quality of life, and position as the center of a top U.S. biopharma hub. Jared also discusses MCEDC's strategic planning process, the importance of reducing uncertainty for companies, and why economic development should be viewed as an investment in long-term community strength.

Throughout the episode, Jared emphasizes that MCEDC is focused on listening, connecting the right people, helping companies navigate available resources, and building a more competitive future for Montgomery County.

Editing and post-production work for this episode was provided by The Podcast Consultant. https://thepodcastconsultant.com/

Jared Smith serves as the President and CEO of the Montgomery County Economic Development Corporation, where he leads economic development initiatives to attract, retain, and expand businesses within key industries in Montgomery County, Maryland.

Jared joined MCEDC in December 2025 after spending more than a decade in Nevada's economic development ecosystem. As Director of Economic Development for the City of Henderson, he supported a community within the Las Vegas Metropolitan Statistical Area of more than two million residents. During his tenure, he played a key role in diversifying a tourism-driven regional economy and supported the creation of more than 20,000 jobs. Previously, as Chief Operating Officer of the Las Vegas Global Economic Alliance, he helped deliver $17.2 billion in regional economic impact, the highest in the organization's history.

His economic development and business experience spans business attraction, retention, and expansion, as well as workforce development and long-term strategic planning. He has collaborated with companies across a wide range of industries, from established businesses to high-growth sectors. Before moving to Nevada, Jared was Director of Business Development at the Baton Rouge Area Chamber and Manager of Business Retention and Expansion at Louisiana Economic Development, where he designed and deployed a comprehensive economic development strategy and outreach program to expand corporate businesses statewide.

Throughout his career, Jared has worked with elected officials at the local and state levels and led various international missions. A Certified Economic Developer, he is an active member of the International Economic Development Council and has been recognized twice, in 2024 and 2022, as one of North America's Top 50 Economic Developers by Consultant Connect. Jared holds an MBA from Southeastern Louisiana University, a bachelor's degree from Louisiana State University, and is a graduate of the University of Oklahoma's Economic Development Institute.

The discussion looks at how incentives support companies across the full business lifecycle, from startups and emerging firms to major employers making large-scale regional investments. Ellen and Rich also examine how recent biohealth activity in Maryland and Virginia reflects the importance of workforce development, site selection, public-private collaboration, and regional thinking. A win in Maryland, Virginia, or Washington, D.C. strengthens the larger BioHealth Capital Region ecosystem.

Ellen also shares how organizations like BHI and Smart Incentives help companies, communities, and decision makers better understand the resources available to support growth, including financing programs, investor tax credits, grants, incubators, accelerators, and other support services. The episode closes with a practical look at transparency, evaluation, and why better data helps policymakers, economic developers, companies, and communities make stronger decisions about incentive programs.

Editing and post-production work for this episode was provided by The Podcast Consultant. https://thepodcastconsultant.com/

Ellen D. Harpel, Ph.D., is the Founder of Smart Incentives (https://smartincentives.org/), which helps communities make sound decisions throughout the economic development incentives process. Launched in 2013, Smart Incentives works with state, local, and national governments to design and implement incentive programs that are effective and responsible, with a focus on compliance monitoring, evaluation, transparency, and lasting community benefits. Ellen is also a Senior Research Fellow with the Center for Regional Economic Competitiveness and an Affiliate Faculty member with the Schar School of Policy and Government at George Mason University.

The discussion also explores the "missing middle" between discovery and commercialization, the role of Entrepreneurs-in-Residence in advancing founders and technologies, and how partnerships among Georgetown, GTV, and BioHealth Innovation are helping to create a more durable and commercially focused innovation pipeline. The guests also reflect on Georgetown's place within the BioHealth Capital Region and what success will look like as the university continues building a stronger culture of entrepreneurship and company creation.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Tatiana Litvin-Vechnyak, Ph.D., is Vice President of Georgetown's Office of Technology Commercialization, where she leads the university's efforts to translate research discoveries into real-world impact through licensing, startup creation, and innovation support. Since joining Georgetown in 2023, she has helped expand the university's commercialization infrastructure, including securing the U.S. Economic Development Administration Build to Scale grant that launched Georgetown Tech Ventures. With more than 20 years of experience in intellectual property, licensing, and business development, she previously served in leadership roles at Rutgers University, where she helped advance major innovation and venture development initiatives. She holds a Ph.D. in Pharmacology and is a Registered Patent Agent.

Christon Hill is Program Manager for Georgetown Tech Ventures in Georgetown University's Office of Technology Commercialization, where he develops programs, partnerships, and founder support pathways that help move promising research toward venture creation, strategic partnerships, and real-world use. With an interdisciplinary background spanning biotechnology, biology, and the humanities, he brings a practical and market-aware approach to early-stage innovation, with experience in venture development, ecosystem building, and translating complex ideas for investors, partners, and non-technical audiences. He is a graduate of Georgetown's biotechnology master's program, a Marine veteran, and a cross-sector operator focused on helping founders and institutions turn strong ideas into credible, actionable opportunities.

Jennifer Butler is a distinguished global commercial executive and strategic leader with nearly 20 years of experience helping biotechnology companies move from early development through commercialization. She serves as an Entrepreneur-in-Residence with BioHealth Innovation and served as Montgomery County's first Executive-in-Residence, a role created through a collaboration between Montgomery County and BioHealth Innovation to provide technical assistance to local biotech startups. Across her career, she has brought a strong commercial perspective to emerging companies, helping founders sharpen strategy, accelerate development, and navigate the path toward growth and commercialization.

Lisa shares how BioForward connects industry, academia, and government to strengthen the state's ecosystem, along with key developments that have brought increased attention to the region, including the expansion of Eli Lilly and Company. She also reflects on Wisconsin's designation as a Biohealth Tech Hub through the U.S. Economic Development Administration and what it means for future growth.

The conversation highlights both momentum and ongoing challenges, particularly around access to early-stage capital and building a stronger pipeline of companies. Lisa outlines what will be required for Wisconsin to continue growing as a competitive biohealth hub.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Lisa Johnson is the Chief Executive Officer of BioForward Wisconsin, the state's member-driven biohealth industry association dedicated to advancing Wisconsin as a global leader in biohealth innovation. In her role, she leads efforts to strengthen the state's ecosystem by connecting industry, academia, and government partners to support company growth, workforce development, and investment attraction.

Lisa brings extensive experience in economic development, public policy, and industry leadership, with a focus on building collaborative environments that drive regional competitiveness. She has been instrumental in positioning Wisconsin as a recognized biohealth hub, including leading the state's successful designation as a Biohealth Tech Hub through the U.S. Economic Development Administration. Through her work, she continues to champion initiatives that support emerging companies, expand access to capital, and foster long-term growth across the biohealth sector.

In this conversation, she explains how exhaustion and sustained stress can quietly affect leadership judgment during critical moments such as fundraising, board interactions, regulatory setbacks, and periods of rapid growth. The discussion explores the signals that investors and advisors may overlook when a founder is struggling behind the scenes, and how the culture of "pushing through" can begin to create risk not only for individuals but for the companies they lead. Dr. Ajmani also shares practical ways founders can stabilize their leadership presence and maintain momentum while protecting their own well-being.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Dr. Sheetal Ajmani is a physician, keynote speaker, and executive coach who helps leaders and founders reclaim their well-being and lead with authenticity. After nearly two decades in clinical medicine, she founded Radiant Living Institute, where she integrates science, psychology, and the mind-body connection to help individuals make meaningful and sustainable changes in their lives and leadership. Dr. Ajmani is also the host of the Essential Self-Care podcast and co-author of the Amazon bestselling book Doctoring, Better. For more information, visit https://www.radiantlivinginstitute.com/.

Dr. Peacock outlines the HeadSMART II study and explains why combining blood biomarkers with neurocognitive testing provides a more complete assessment than biology alone. Dr. Kuehl discusses how multi-modal data, integrated through artificial intelligence, can generate an objective score to support real-time clinical decision-making and help identify patients at risk for persistent symptoms. The episode also highlights BrainBox's leadership, including CEO Donna Edmonds, a member of the BioHealth Innovation Board of Directors, and the company's role in advancing objective mTBI testing.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Dr. W. Frank Peacock IV is Professor of Emergency Medicine at Baylor College of Medicine. Chief Medical Officer at AseptiScope, and the founder of both a contract research organization called Comprehensive Research Associates, LLC and a medical education company named Emergencies in Medicine, LLC. Dr. Peacock received his medical degree from Wayne State University Medical School and completed his Emergency Medicine training at William Beaumont Hospital. He has >900 peer reviewed publications and is also the co-editor of multiple medical textbooks on heart failure, acute coronary syndromes, and traumatic brain injury.

Dr. Damon R. Kuehl is the Vice Chair of Research and Academic Affairs and Professor in the Department of Emergency Medicine at Virginia Tech, School of Medicine. He completed Medical School at University of Minnesota Medical School and his Emergency Medicine Residency at Stanford University. He has also completed residencies in Preventive Medicine and a Research Fellowship in the Center for Policy and Research in Emergency Medicine, at Oregon Health and Science University. Dr. Kuehl's research primarily focuses on diagnostic and prognostic uncertainty in brain injury. He is a lead investigator for HeadSMART II and for HeadSMART Geriatrics, a NINDS funded 3 year study to develop a diagnostic tool for head trauma in older adults. He is the founder of the Carilion Brain Injury Center and also an investigator with the Virginia Tech Center for Biomechanics studying the boundary conditions associated with injuries in older adult falls.

The conversation explores how the partnership between Prince William County, George Mason University, and the City of Manassas came together, outlining the distinct roles each plays in advancing a shared strategy. The episode also introduces the NISA program, detailing how it supports companies seeking a soft-landing pathway into the district, the types of organizations best suited for the program, and the facilities, talent, and collaborative resources participants can access both immediately and over time.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Jaehan Park is Founder and CEO of NAUGEN, a global innovation accelerator advancing novel technologies across life sciences and deep tech. With more than 25 years of experience in strategy and business development, he has led collaborations spanning cancer immunotherapy, vaccines, and biologics with global pharmaceutical companies and academic institutions. He leads the NISA Program in partnership with George Mason University and serves as a Mentor-in-Residence at KIC DC, supporting international startups entering U.S. markets.

Amy Adams is Executive Director of George Mason University's Institute for Biohealth Innovation, where she advances biohealth research and innovation across more than 300 faculty and thousands of students. Her work focuses on partnerships, shared research infrastructure, and building hubs that connect academia with industry. She is co-leading the development of the Innovation District anchored at Mason's SciTech campus and serves on the boards of BioHealth Innovation and the Association of University Research Parks.

Christina Winn leads the Prince William County Department of Economic Development, guiding investment, business growth, and redevelopment efforts across one of Virginia's largest counties. She is overseeing the development of a research-driven Innovation District in partnership with George Mason University and the City of Manassas, supported by a GO Virginia grant. Her career includes leading large-scale economic development initiatives that have driven significant capital investment, job creation, and national visibility for the region.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Matthew Keesan is Vice President and GM of Quantum Platform at IonQ and a member of the BHI Board. He joined IonQ in 2017 to lead the development of the company's Quantum OS, the software stack that controls IonQ's quantum computers. In 2021, he oversaw the launch of IonQ's Harmony systems on Amazon Braket, Microsoft Azure Quantum, and Google Cloud, making IonQ the first quantum hardware provider available across all three hyperscalers. He built IonQ's security function to meet commercial and government frameworks, including SOC 2, NIST 800-171, NIST 800-53, and ISO 27001, and established a globally distributed operations team managing IonQ's fleet of quantum computers across the United States and Europe.

Before joining IonQ, Keesan served as CTO of the restaurant technology company Ando, which was acquired by Uber, and advised startups in manufacturing, e-commerce, and identity-as-a-service. He also helped create the technology behind the interactive HBO series Mosaic with Steven Soderbergh. He holds patents in quantum compilation, hybrid quantum computation, and quantum control automation, and has co-authored papers published in Nature and Physical Review A.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Whurley is the founder and CEO of Strangeworks, an Eisenhower Fellow, a Senior Member of the IEEE, founder of the Quantum Computing Standards Workgroup at the IEEE, the first Ambassador to CERN and Society, and co-author of "Quantum Computing for Babies" and the forthcoming "Quantum Computing for Dummies." He previously served as a Managing Director at Goldman Sachs following its acquisition of his startup Honest Dollar. Before that he founded Chaotic Moon Studios, which was acquired by Accenture.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Juan Pablo Segura is the Secretary of Commerce and Trade for the Commonwealth of Virginia. He leads 13 agencies focused on economic growth, business development, and industry expansion across the state. Before entering public service, Segura spent his career building companies in the digital health sector, most notably as a founder of Babyscripts, a widely adopted maternity care platform. His work has been recognized by Startup Health, CTIA, EY, and the White House. He is a CPA and a graduate of the University of Notre Dame, and he lives in Henrico, Virginia with his family.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Dr. Kolaleh Eskandanian is a nationally recognized leader in pediatric health innovation with more than twenty years of experience across academia, government, and industry. She previously served as Vice President and Chief Innovation Officer at Children's National Hospital, where she founded Innovation Ventures and secured significant federal funding, patents, and licensed technologies. She now leads the BARDA-funded SPARK Accelerator Hub for Pediatrics and serves as Chief Strategy and Innovation Officer at Compremium AG, while also supporting early-stage innovators as an angel investor with Citrine Angels.

Dori Jones is the Co-Founder and CEO of AcQumen Medical, a medtech company developing UltraTrac, the first ultrasound-guided impedance technology designed for rapid assessment of hemodynamics in critically ill infants and children. She brings nearly two decades of experience across R&D, clinical education, and commercialization roles supporting cardiac and critical care devices at organizations ranging from early startups to Abbott and Medtronic. Her commitment to pediatric innovation is shaped in part by her experience as the mother of a NICU and PICU patient.

Dr. Jugal Suthar is the Co-Founder and CEO of Vesynta, a precision medicine company developing the DosoLogic platform, the first marketplace-enabled precision prescribing software aimed at improving accuracy and safety for every patient. His background includes clinical work as a hospital pharmacist and roles in drug development in the pharmaceutical industry. His PhD in precision medicine fuels his focus on bringing personalized dosing insights to populations often underrepresented in clinical research.

Eldering also reflects on the company's path through the BioHealth Capital Region Crab Trap Competition. After a second‑place finish a few years earlier, Perfusion Medical returned to the stage and won the 2025 competition. He shares what that experience has meant for the team and why building the company in the BioHealth Capital Region—particularly from a Virginia base—has been a strategic advantage.

The conversation moves through the role of early federal funding and programs like SBIR/STTR in de‑risking breakthrough therapies, and how university research partnerships have strengthened PM‑208's development. Eldering highlights how public‑private collaboration has shaped the company's progress and made it possible to push a complex medical solution toward patients more quickly.

Editing and post-production work for this episode was provided by The Podcast Consultant - https://thepodcastconsultant.com/0

About Gerard Eldering Gerard Eldering is the CEO of Perfusion Medical and a nationally recognized expert in technology transfer and venture formation. Since becoming an entrepreneur in 2007, he has helped launch more than a dozen startups, raised more than $15 million in seed funding, and led the turnaround and sale of a technology consulting firm. Before founding Perfusion Medical, he built and led The MITRE Corporation's Technology Transfer Office. Eldering is a U.S. Air Force veteran who served as a helicopter pilot and instructor. He holds a B.A. in Physics, an M.B.A., and is a registered patent agent.

Editing and post-production work for this episode was provided by The Podcast Consultant: thepodcastconsultant.com

Councilman Brian Knudsen was elected to represent Ward 1 in 2019 and re-elected in 2024, continuing his long-standing commitment to public service and community-building in Las Vegas. On December 21, 2022, he was named Mayor Pro Tem. Brian has been instrumental in driving the transformation of the Las Vegas Medical District and expanding public health infrastructure throughout the city. He serves on several boards, including the Southern Nevada Health District and the Regional Transportation Commission, and is a vocal advocate for policies that strengthen healthcare, public safety, and inclusive economic development.

Jamie Schwartz, MBA, is Director of Industry Engagement at the University of Nevada, Las Vegas (UNLV) Office of Economic Development and President of the Board for BioTech Vegas. With deep experience in public-private partnerships and academic-industry collaboration, she works at the intersection of research, innovation, and commercialization to strengthen Southern Nevada's biotech and health innovation landscape.

Vance Farrow serves as the Healthcare Industry Specialist for the Nevada Governor's Office of Economic Development. His work focuses on attracting and expanding healthcare businesses throughout the state, aligning talent development efforts, and building the infrastructure needed to support a robust biohealth sector. He plays a critical role in shaping state policy and investment strategies for the industry.

Topics include Maryland's recent recognition as a Top 3 biopharma hub, the decision to prioritize Life Sciences and Computational Biology as "Lifehouse" sectors, and how the state is leveraging the BioHealth Capital Region identity to unite and expand its regional leadership. He also outlines Maryland's case for investment and why collaboration will be central to "Winning the Decade."

Editing and post-production work for this episode was provided by The Podcast Consultant.

The Honorable Harry Coker, Jr. was appointed by Governor Wes Moore as Maryland's Secretary of Commerce in 2025. He is a retired senior executive from the CIA and NSA, former National Cyber Director at the White House, and a career Naval Officer. Coker's leadership is shaped by decades of public service at the highest levels of national security and technology. At the Maryland Department of Commerce, he leads efforts to build an equitable, competitive economy centered around innovation, inclusion, and impact.

In this episode of BioTalk with Rich Bendis, Stefanie Trop, Ph.D., Director of Life Sciences at the Maryland Department of Commerce joins the conversation to discuss Maryland's position as a leading life sciences hub. Stefanie shares how the Department of Commerce supports company attraction and growth through programs like Global Gateway, and how it's amplifying the state's recent #3 biopharma hub ranking. The discussion also explores Maryland's unique ecosystem, including the work of the Governor's Life Sciences Advisory Board, the state's leadership in computational health, and the importance of industry collaboration during BioHealth Capital Region Week.

Editing and post-production work for this episode was provided by The Podcast Consultant. Dr. Stefanie Trop brings a unique blend of hands-on scientific expertise and high-level strategic insight. With a Ph.D. in Molecular Microbiology and Immunology, she has worked at the ground level in immunology, clinical trials, and vaccine development, while also driving growth through scientific partnerships and business development. Her deep understanding of the science and passion for problem solving guides her ability to build effective collaborations that advance both innovation and commercial success.

At the Maryland Department of Commerce, Stefanie works to connect Maryland's life sciences companies with national and global resources, expanding the industry's impact at home and globally. In current and prior roles, she bridges communication gaps between scientific and business teams, ensuring that customer needs translate into innovative products and business wins.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Guest Bio

Dr. Stacey Adam is Vice President of Science Partnerships at the Foundation for the NIH (FNIH), where she leads major public-private partnerships including the RECOVER-Treating Long COVID initiative, multiple Biomarkers Consortium projects, the Accelerating Medicines Partnerships (AMPs), and the Lung-MAP clinical trial. She also leads efforts to design new public-private partnerships focused on pediatric medical devices, cancer systems biology, and the advancement of New Approach Methodologies (NAMs) through the Validation and Qualification Network. Previously, Dr. Adam worked at Deloitte Consulting and completed a postdoctoral fellowship at Stanford University School of Medicine. She holds a PhD in Pharmacology with a Certificate in Mammalian Toxicology from Duke University.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Dr. Helen Sabzevari is the President and CEO of Precigen, Inc., and a leading expert in immunotherapy-based therapeutics. She previously served in executive roles at Compass Therapeutics and Merck KGaA/EMD Serono, where she advanced numerous immuno-oncology programs. Dr. Sabzevari began her career at the National Cancer Institute and has been widely recognized for her leadership and scientific contributions, including honors from NIH, SITC, and Forbes.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Lara Mangravite, PhD, is Executive Director at Digitalis Commons, a nonprofit organization developing scalable, frontier-advancing solutions to critical problems in health. She previously served as President of Sage Bionetworks, where she led initiatives to build and share multi-modal human data for biomedical research. Lara earned her BS in Physics from Pennsylvania State University, her PhD in Pharmaceutical Chemistry from the University of California, San Francisco, and completed a postdoctoral fellowship in cardiovascular pharmacogenomics at the Children's Hospital Oakland Research Institute.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Amy C. Hay is the Chief Business and Strategy Officer at the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience and MD Anderson Cancer Center. She brings decades of experience in oncology care, strategic growth, and healthcare innovation to her role, where she leads business strategy, partnerships, and long-term growth initiatives. Prior to CTMC, Amy held leadership roles at Varian (a Siemens Healthineers company), MD Anderson Cancer Center, and several global consulting efforts focused on advancing cancer care. Her career spans work across the U.S. and internationally, with a focus on driving innovation, commercialization, and patient access in complex health systems.

Sam Tetlow is the Founder and CEO of Grant Engine, where he leads a team focused on securing funding for leading life science companies through SBIR, BARDA, ARPA-H, NIH, DoD, and NSF opportunities. A serial entrepreneur and experienced investor, Sam has contributed to the success of companies like EpiCypher, Gentris Corporation, and Tranzyme Pharma (IPO in 2011). With over two decades of experience and a 6.2x return on invested capital, he brings deep knowledge of the strategic, financial, and technical aspects of life science commercialization. Sam holds a B.S. in Aerospace Engineering from Worcester Polytechnic Institute and an MBA from UNC's Kenan-Flagler Business School.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Rick Wieczorek has been in the credit union industry for over 40 years and currently serves as President and Chief Executive Officer of the NIH Federal Credit Union. Since taking the helm in 2013, he has focused on making NIHFCU the preferred provider of financial services for the healthcare and biomedical communities. His previous roles include President and CEO of Mid-Atlantic Federal Credit Union and CFO of NRL Federal Credit Union, where he became recognized as an expert in asset liability management and wealth strategy. Rick has also served as Chairman of the MD|DC Credit Union Association Board of Directors. A graduate of George Mason University with an MBA from George Washington University, Rick began his career as a teller and brings deep expertise and passion to his leadership in mission-driven financial services.

They discuss the engineering challenges of building clinical-grade hardware for hospitals with limited infrastructure, the company's growth from Maryland's Relevant Health accelerator, and the deployment of over 350 devices across East and West Africa. Sona also talks about Neopenda's next wave of products, lessons in balancing cost and quality, and the importance of community, resilience, and mission-driven entrepreneurship.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Sona Shah is the CEO and Co-founder of Neopenda, a company dedicated to improving healthcare access in emerging markets. Neopenda develops innovative medical technologies—such as the neoGuard system—designed to help healthcare providers deliver high-quality care in low-resource settings. The company's mission is to make life-saving technology available where it's needed most.

Sona's path into global health innovation began during a semester teaching primary school in Kenya, where she witnessed firsthand the challenges faced by under-resourced healthcare systems. That experience, paired with her background in biomedical engineering, inspired her to co-found Neopenda in 2015. Since then, the company has focused on delivering scalable, impactful solutions to countries including Kenya, Uganda, and Ghana, with a long-term goal of reaching the next billion people who could benefit from better access to care.

She remains committed to advancing tech-driven healthcare solutions that make a meaningful difference in the world's most underserved communities.

Alex breaks down the potential consequences of FDA workforce cuts, particularly for small and mid-sized biotechs that depend on regulatory guidance, and offers perspective on how HHS and NIH budget proposals could reshape the national innovation infrastructure. The conversation covers everything from the impact of tariffs on manufacturing and supply chains to the slowing pace of M&A activity and venture capital investment trends. Alex also shares his insights on IPO strategy shifts, and whether the current biotech environment is poised for a rebound—or a broader realignment with global competitors. This is a must-listen episode for anyone navigating the uncertain waters of biotech in 2025.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Alex Philippidis is the Senior Business Editor at Genetic Engineering & Biotechnology News (GEN). Specializing in biopharma business news and industry issues, Alex joined GEN in 2011 after covering research institutes at GenomeWeb and editing the BioRegion News newsletter. With over 20 years of experience in journalism, Alex has reported on various topics for newspapers and has been featured in major media outlets such as the New York Times and the BBC.

Dr. Hemingway also highlights Ecphora Capital's impact, having deployed $15 million in the last two years, and reveals the firm's strategy for future investments, including SPVs and a dedicated fund. With deep experience in medtech commercialization, strategic partnerships, and early-stage investing, she offers valuable perspectives on where the industry is headed in 2025 and how companies can thrive in an evolving biotech ecosystem.

Tune in for a compelling conversation on innovation, investment, and the future of biotech in the BioHealth Capital Region.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Dr. Deborah Hemingway is the Founder and Managing Partner of Ecphora Capital, a medtech venture capital firm in Baltimore, Maryland. Ecphora Capital leverages first-look access at world-class medical research and manufacturing institutions and is the first and only entity to achieve the top level of a state tax credit program that refunds 75% of their investment.

Additionally, Dr. Hemingway has profound involvement in the entrepreneurial landscape, having founded, invested in, and held board positions for 53 startup companies over twenty years. She has meticulously sharpened her acumen in medical device commercialization, strategic growth, and investing. She is on the board of directors for Mi-Helper and Novel Microdevices. Dr. Hemingway holds a Ph.D. in biophysics from the University of Maryland, College Park.

Dean Varshney discusses the launch of the Artificial Intelligence Interdisciplinary Institute at Maryland (AIM) earlier this year. He shares insights into the vision behind AIM, the strategic hiring of new faculty, the allocation of seed grants, and the development of academic programs in AI, all solidifying UMD's position as a leader in this rapidly evolving field.

The conversation also delves into the University of Maryland Institute for Health Computing (UM-IHC), which recently marked its two-year anniversary. Dean Varshney highlights the institute's achievements, including its partnerships with organizations like the FDA and NIH, patent submissions, and collaborations with AstraZeneca and 20/20 Gene Systems. He explains how UM-IHC's efforts are reshaping the intersection of health and technology.

Rich and Dean Varshney discuss UMD's commitment to innovation and its role in tackling national challenges through interdisciplinary education, cutting-edge research, and collaborations with industry partners, government agencies, and research institutions. They also reflect on the university's integral role within the BioHealth Capital Region and its contribution to advancing scientific discovery, economic growth, and regional leadership in biotech and health innovation.

Tune in to hear how UMD's focus on AI and health computing is shaping the future of education, research, and collaboration.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Amitabh Varshney is Dean of the College of Computer, Mathematical, and Natural Sciences and a Professor of Computer Science at the University of Maryland, College Park. Varshney is currently exploring applications of virtual and augmented reality in several areas, including education, healthcare, and telemedicine. His research focuses on exploring the applications of high-performance visualization in engineering, science, and medicine. He has worked on a number of research areas including visual saliency, summarization of large visual datasets, and visual computing for big data. He has served in various roles in the IEEE Visualization and Graphics Technical Committee, including as its Chair (2008–12). He received the IEEE Visualization Technical Achievement Award in 2004. He is a Fellow of IEEE and a member of the IEEE Visualization Academy.

She also highlights the unique challenges in developing pediatric medical countermeasures and the importance of partnerships with organizations like Rainbow Babies, Mass General, and others. Additionally, Dr. Eskandanian shares insights into the hospital's role in fostering innovation through the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) and the Children's National Research and Innovation Campus.

Join us for an engaging conversation about the future of pediatric healthcare, the opportunities for innovation, and how the SPARK Accelerator is paving the way for advancements that will improve the lives of children worldwide.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Kolaleh Eskandanian, Ph.D., M.B.A., P.M.P. is Vice President and Chief Innovation Officer at Children's National Hospital, reporting to hospital's Executive Vice President, Physician-In-Chief and Chief Academic Officer. In this capacity, she oversees the Office of Innovation Ventures, the Sheikh Zayed Institute's R&D operations, and has a leadership role in the development of the Children's National Research and Innovation Campus (opening 2020).

She is also the executive director of the FDA-funded National Capital Consortium for Pediatric Device Innovation (NCC-PDI), focused on accelerating the path to market for pediatric devices. Eskandanian works with a large network of small and large businesses, nonprofits and government agencies –addressing the unmet medical needs of children. She is the producer of an annual innovation competition that supports small businesses who demonstrate the ability to address a significant medical need in the pediatric space.

Eskandanian's expertise includes the full spectrum of product development activities, having held management positions at Accenture, a global management consulting firm, where she directed major product launches for clients. Eskandanian is the co-PI on the FDA-funded Global Pediatric Clinical Trials Network grant and the CTSI-CN lead of the Orphan Product Accelerator.

Eskandanian's own innovations are in the market space, used by millions. She is the lead inventor of the first-ever adverse event reporting system, initially deployed in a research academic environment. This technology and its derivatives have now been in the market for over 10 years. She has had leadership roles in the development of the first web-based trouble entry management system for a Fortune 100 company in the telecommunications sector. She has been a key contributor in securing over $40 million in government funding for two large research enterprises. Prior to joining Children's National, Kolaleh held positions with Intelsat, Accenture and Georgetown University. Her background is in mechanical engineering with a PhD in operations science and an MBA from American University Kogod School of Business.

Bill outlines MCEDC's priorities for the upcoming year, emphasizing economic growth, investment opportunities, and fostering collaborations that make Montgomery County a thriving ecosystem for business and life sciences.

Bill Tompkins is the President and Chief Executive Officer of the Montgomery County Economic Development Corporation (MCEDC), based in Rockville MD. He leads a team of twenty-five diverse professionals who work to fulfill the mission of making Montgomery County one of the best, most diverse and equitable places to be in business in the country. Bill was previously Executive Vice President and Chief Operating Officer and has been with MCEDC since January of 2019.

Bill has a seasoned background in marketing, business operations, strategic planning, and nonprofit management, with most of his career serving as a senior executive in the media and entertainment industries with Fortune 500 companies. Bill also ran a consulting practice which advised companies on strategic business opportunities and brand transformation strategies.

From May 2014 until August 2015, Bill was Vice President, Advertising and Marketing at The Philadelphia Tribune. He made a strategic investment in The Tribune to help ensure the long-term sustainability of Black media in the US.

In July 2012, he was named President and CEO of the National Newspaper Publishers Association, a Washington based organization, which represents over two hundred Black owned and operated newspapers across the nation.

Bill joined the Eastman Kodak Company in 2000 as Chief Marketing Officer for the Entertainment Imaging Business unit and became Vice President and General Manager of the Motion Picture Film Group while also serving as a corporate vice president.

Prior to Kodak, Bill spent nineteen years from 1982 until 2000 at The Washington Post Newspaper in a variety of executive positions. His most recent position there was Vice President of Marketing with most of his career spent in the Advertising and Circulation Departments.

Bill has been in active leadership positions on several nonprofit Boards including the Mosaic Theater Company of DC where he is Treasurer and the former Chair of the Board, Rockville Economic Development (REDI), Worksource Montgomery and the Advisory Boards of the Universities at Shady Grove and Montgomery Moving Forward.

He was previously Chairman, National Kidney Foundation, National Capital Area, member, Board of Directors, California Chamber of Commerce, the Advertising Council, the Studio Theatre, The Washington Convention and Visitors Association, The Boys and Girls Clubs of Greater Washington, the American Black Film Festival Advisory Board, and The Helen Hayes Awards Committee. He is also a member of the Executive Leadership Council, and a graduate of Leadership Washington.

Bill is a member of the Economic Club of Washington, the Executive Leadership Council, and a graduate of Leadership Washington.

Bill received his MBA from the Harvard Business School where he was a General Motors Fellow and received his BA in Economics, magna cum laude from Tufts University.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Ric explains how Linshom is addressing critical gaps in respiratory monitoring by bringing operating-room-quality data to patient bedsides and homes. Talia shares insights from the engineering side, highlighting the challenges and breakthroughs in developing reliable and user-friendly technology.

The conversation explores Linshom's roots in the BioHealth Capital Region and how its partnerships and resources have been instrumental to the company's growth. Talia reflects on her experience presenting at the Crab Trap Competition, and Ric discusses how this recognition aligns with Linshom's broader visibility and growth objectives.

Looking ahead, Ric and Talia provide a glimpse into Linshom's future, including upcoming milestones and advancements that promise to further revolutionize respiratory care. Don't miss this episode filled with innovation, collaboration, and a vision for transforming patient safety.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Richard Hughen's thirty years of medical device experience spans three Fortune 500 and three start-up companies with two successful exits to date. He is currently CEO of Linshom Medical, a start-up that is first to deliver operating room quality respiratory data to the patient bedside and home. Ric was an investor and member of the executive team that built start-up CSA Medical, from a technology license (U.S. Navy) through product development, animal trials, clinical trials, five FDA clearances, CE mark, three rounds of funding ($50M), commercial growth and a 2019 sale to Steris. Ric was Managing Director of LearnWare, a life science focused e-learning start-up, which was successfully built and sold to a private equity fund. He is currently a reviewer for the National Science Foundation's SBIR/STTR program, an Entrepreneur in Residence for Johns Hopkins Tech Ventures, an advisory board member of George Mason University's Bioengineering Alliance and a site miner for TEDCO at the University of Maryland Medical Center in Baltimore. Earlier in his career, Ric led various senior management, marketing, training and sales teams for Johnson & Johnson, BD, Abbott and Cordis. Ric holds MBA and BS degrees from The Pennsylvania State University.

Talia Feldman is a software engineer at Linshom Medical, an innovative healthcare technology company at the forefront of transforming respiratory monitoring. Talia received a B.S. in Computer Science with a concentration in Artificial Intelligence from the University of Delaware. Upon graduation she worked as a software engineer in the Maritime Division at Leidos. Now combining her technical skills with a passion for innovation, Talia supports Linshom Medical's development of providing continuous predictive respiratory monitoring to improve patient care.

Dr. Edwards explains the groundbreaking technology behind MedPhlow's platform and how it is poised to transform emergency care. He also highlights the impact of investor partnerships, such as those with Virginia Venture Partners, and discusses MedPhlow's next milestones in its mission to make emergency medicine more efficient and accessible.

As a part of the BioHealth Capital Region, Dr. Edwards reflects on the advantages of being based in this vibrant hub of innovation and his contributions as a BioHealth Innovation (BHI) board member. Tune in to learn about the future of MedPhlow and the inspiring work being done to advance life-saving solutions in healthcare.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Dr. Edwards was previously co-founder of Kaléo, Inc. a pharmaceutical company in Richmond, VA. During his 16 years at Kaléo, he held several executive management positions including Chief Science Officer where he was responsible for overall scientific strategy and all pharmaceutical development programs; Chief Medical Officer responsible for developing a medical affairs team and capability while operationalizing the Company's clinical program strategy; and Vice President – Innovation, overseeing Kaleo's research and development pipeline and overall new product strategy.

Dr. Edwards is the co-inventor of multiple marketed products, including AUVI-Q, epinephrine auto-injector for the treatment of allergic emergencies (anaphylaxis), is named on over 215 issued and patent-pending applications, and is a published author on numerous scientific publications.

Dr. Edwards also continues to serve his community by volunteering on a local rescue squad, including responding to 911 calls and training paramedics in pre-hospital emergency care.

Dr. Edwards. obtained his B.S. in Biology, Ph.D. in the Pharmaceutical Sciences, and Doctor of Medicine degrees at Virginia Commonwealth University/Medical College of Virginia.

In this episode, Eric shares Cerillo's mission to combat Eroom's Law—the increasing cost and time in drug development—through affordable and accessible research tools like the Stratus and Alto microplate readers. We also dive into the impact of Cerillo's co-culture duet system, which is transforming cellular interaction studies in fields such as antimicrobial resistance and biofuel development.

Learn how being located in the southern part of the BioHealth Capital Region has supported Cerillo's growth and hear about the company's future plans to further accelerate biological research. Don't miss this conversation about the innovations driving a new era in cellular analytics.

Eric Mayton is the President, CEO, and Chairman of the Board at Cerillo, a Charlottesville, VA based cellular analytics firm focused on increasing the efficiency, reproducibility, and standardization of data collection in scientific research and product development. Eric spent the first decade of his career managing academic and commercial laboratories before earning his MBA from the University of Richmond in 2017.

After stints in private equity and management consulting, Eric returned to the biotech industry in 2020 as CEO of Cerillo, a University of Virginia spin-out. Eric holds a B.S. in Chemistry from the University of Virginia, a M.S. in Biochemistry from Virginia Commonwealth University, and a M.B.A from the University of Richmond.

Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).

Tune in as Rachel shares the current priorities at JLABS, highlighting the diversity of its tenant portfolio, which spans MedTech, Pharma, and Integrated Healthcare Solutions. She also discusses how JLABS companies benefit from the support and resources available through Johnson & Johnson, including access to valuable connections, mentorship, and funding opportunities via JJDC.

Located in the heart of the BioHealth Capital Region, JLABS @ Washington, DC is well-positioned to drive collaboration and ecosystem growth. Rachel sheds light on the unique advantages of this strategic location and shares her views on addressing the challenges faced by life science startups, from funding access to investment connectivity, and the vital steps needed to elevate the region's biohealth ecosystem.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Rachel is responsible for setting the strategic direction and overseeing all operational activities for JLABS @ Washington, DC. Her responsibilities include P&L management, external engagement, innovation sourcing, portfolio management, and operational excellence in collaboration with the team responsible for the site and the region. In addition to managing the business of JLABS, Rachel is responsible for the process of evaluating, selecting and accelerating a strong portfolio of innovators connected to JLABS @ Washington, DC, which supports companies across the broader region.

Prior to this role, Rachel served as the inaugural Director of the BARDA Alliance for Johnson & Johnson Innovation. As BARDA Alliance Director, she was responsible for managing BLUE KNIGHT™, a joint initiative between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), which aims to stimulate the innovation and incubation of science and technologies. Rachel led the strategic direction, alliance management, and oversight of all operational activities related to BLUE KNIGHT™, including managing the sourcing and selection of high potential companies for JLABS locations and developing global programming including the annual BLUE KNIGHT™ Symposium.

Before joining JLABS, Rachel was the Chief of Staff for the National Evaluation System for health Technology Coordinating Center (NESTcc)—an initiative of the Medical Device Innovation Consortium (MDIC)—that was established with funding from the U.S. Food and Drug Administration (FDA) and was recognized in September 2019 as one of the first collaborative communities with participation by the FDA. Prior to joining NESTcc, Rachel worked at PCORI, helping to launch the Patient-Centered Clinical Research Network (PCORnet), a national effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United States.

Rachel received her MBA from Georgetown University and MPH in global health policy from The George Washington University.

Dr. Gupton shares how Phlow is addressing vulnerabilities in the U.S. pharmaceutical supply chain by producing critical medicines domestically, and how the Medicines for All Institute is reshaping the way drugs are made by reducing costs and streamlining production. Drawing on his extensive experience in the pharmaceutical industry, Dr. Gupton discusses the ongoing challenges of ensuring that lifesaving medicines reach those in need worldwide.

The discussion also touches on the future of pharmaceutical manufacturing, from emerging technologies like continuous processing to green chemistry's role in creating more sustainable production methods. Dr. Gupton provides insight into how partnerships and collaboration are vital to accelerating these innovations.

Join the conversation to hear about the impactful work being done to transform drug manufacturing and access on a global scale.

Dr. Frank Gupton is a professor at Virginia Commonwealth University and holds joint appointments in the Departments of Chemistry and the Department of Chemical and Life Science Engineering. He is the Floyd D. Gottwald Chair of Pharmaceutical Engineering and also serves as Department Chair of the Chemical and Life Science Engineering Department. His thirty-year industrial career centered on the development and commercialization of chemical processes for pharmaceutical applications. Dr. Gupton's research group is currently focused on the development of continuous processing technology to facilitate the discovery, development and commercialization of drug products. Prior to joining the faculty at Virginia Commonwealth University, Dr. Gupton served as the Executive Director of North American Process Development for Boehringer Ingelheim Pharmaceuticals and led the commercialization of the widely prescribed HIV drug nevirapine. Dr. Gupton received his Bachelors of Science degree in chemistry from the University of Richmond and graduate degrees in organic chemistry from Georgia Tech and Virginia Commonwealth University.

Dr. Gupton's research efforts have focused on streamlining pharmaceutical processes, particularly in the area of active ingredients, by employing the principles of process intensification which include the use of innovative chemistry, novel continuous manufacturing platforms, and new and more efficient catalysts for pharmaceutical applications. The research group's efforts are guided and driven based on both financial and economic impact that can be derived from this effort. Dr. Gupton is the recipient of the 2018 American Chemical Society Award for Affordable Green Chemistry, and in the same year, he received the Presidential Award for Green Chemistry. In 2019 he received the Peter J. Dunn Award for Green Chemistry and Engineering Impact in the Pharmaceutical Industry from the ACS Green Chemistry Institute Pharmaceutical Round Table. These awards were associated with Professor Gupton's work on the development of a highly efficient process to produce nevirapine, a first-line treatment in HIV therapy.

Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).

Peter introduces Emmes, its growth as a full-service CRO, and the recent partnership with New Mountain Capital that has accelerated global acquisitions and diversified services. He also discusses the formation of the Emmes Group, which includes Veridix AI, and the latest partnership with Mimansa AI, highlighting the impact of AI in clinical research.

The conversation also covers the strategic importance of Rockville, Maryland, as Emmes' headquarters and why Montgomery County is an ideal location. Peter wraps up by outlining Emmes' future growth plans.

About Peter Ronco: Peter Ronco is the CEO of Emmes, with extensive global experience in pharmaceutical development. He oversees the strategic and operational aspects of Emmes, a leading CRO operating in over 30 countries. Prior to Emmes, Peter held senior roles at Janssen R&D and Bristol Myers Squibb.

Tune in to BioTalk for a focused discussion with Peter Ronco on Emmes' growth, AI in clinical research, and the future of global drug development.

Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).

Kelly Services, a global leader in workforce solutions, plays a pivotal role in connecting talent with opportunities across various industries, including science, engineering, technology, and telecommunications. Brad and Sarah provide valuable insights into how Kelly Services is adapting to the evolving needs of the biotech sector, from commercial enterprises to government agencies.

The discussion covers various topics, including the current talent landscape in the BHCR, strategies for maintaining a robust pipeline, and the challenges of retaining top talent in an increasingly competitive market.

Additionally, we learn about Kelly's upcoming virtual job fair in September (https://bit.ly/3yMuiRm), an event for those looking to connect with opportunities in the biotech sector and the 2024 Kelly Global Re:work Report (https://bit.ly/3SSVhBl), offering listeners valuable insights into the future of work and workforce trends globally.

About Brad Sibbald: Brad Sibbald is the Vice President of Kelly Science and Clinical, with over 15 years of experience in workforce solutions and consultative services. With a background in biochemistry and a passion for innovation, Brad is committed to driving forward-thinking solutions in the biotech industry.

About Sarah Porter: Sarah Porter is the Vice President of Government Solutions at Kelly Services, leading the sales and operations for Kelly Government Solutions. With nearly 20 years of experience in the government industry, including a role at the NIH, Sarah has a deep understanding of the complexities of workforce solutions in the federal sector.

Tune in to BioTalk for an insightful discussion with Brad Sibbald and Sarah Porter as they explore workforce trends, talent strategies, and the evolving landscape of biotech and government solutions in the BioHealth Capital Region and beyond.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Johann de Bruyn opens the conversation by introducing TASK Applied Science and its collaborative relationship with the U.S. He explains the genesis of Bio Centrifuge Africa, a business plan competition inspired by the BioHealth Capital Region's Crab Trap, designed to bridge the gap between South Africa's emerging biotech sector and the established BHCR.

Ethan Hunter, co-founder of Immobazyme, discusses his company's pioneering work in precision fermentation and the growing impact it has across various industries. He reflects on the significance of winning Bio Centrifuge Africa and the exciting opportunity to compete in the 9th Annual Crab Trap in Maryland this September.

Dr. Carla Eksteen shares her research journey in cancer immunotherapy and the vital role her work plays in advancing healthcare in South Africa. She talks about the opportunities provided by Bio Centrifuge Africa and her upcoming trip to Maryland as part of the competition winners.

This episode offers a fascinating look at how South African innovators are making their mark on the global biotech stage and emphasizes the power of international partnerships in driving the industry forward.

About Johann de Bruyn: Johann de Bruyn is the CEO of TASK Applied Science, committed to integrating Africa into the global clinical research landscape. With a diverse background in management, Johann is passionate about advancing healthcare and elevating Africa's role in global clinical research.

About Ethan Hunter: Ethan Hunter is the Chief Operations Officer and co-founder of Immobazyme, a South African biotechnology company specializing in precision fermentation. With a strong foundation in plant biotechnology and molecular biology, Ethan is leading Immobazyme's innovative efforts in the biotech industry.

About Dr. Carla Eksteen: Dr. Carla Eksteen is a Postdoctoral Research Fellow at Stellenbosch University, focusing on cancer research and immunotherapy. With significant experience in tackling chemotherapy treatment resistance and tumor immunogenicity, Dr. Eksteen is dedicated to advancing precision oncology in South Africa.

Tune in to BioTalk for an enlightening discussion with Johann de Bruyn, Ethan Hunter, and Dr. Carla Eksteen as they share their experiences and vision, linking South African biotech innovation with the BioHealth Capital Region.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Craig Gravitz and Jenica Patterson share their educational and career backgrounds, setting the stage for a discussion about ARPA-H and its various initiatives. They provide insights into how ARPA-H differentiates itself from other agencies like HHS and NIH, while also highlighting their collaborative efforts.

Listeners will learn about the Project Accelerator Transition Innovation Office (PATIO) and its crucial role within ARPA-H. Jenica Patterson discusses her portfolio, including key areas and projects, and provides details on the new women's sprint for health initiative and its funding tracks.

The conversation highlights examples of ARPA-H investments and milestones achieved, as well as the processes involved in determining future programs and investment priorities. Craig and Jenica also discuss the unique Entrepreneur in Residence (EIR) program and how it supports ARPA-H projects.

About Craig Gravitz: Craig Gravitz is designing and implementing the transition and commercial strategy for the Advanced Research Projects Agency for Health (ARPA-H). Prior to joining ARPA-H, Mr. Gravitz launched and ran a research and development program at the Defense Logistics Agency. He is a licensed attorney and has previously serviced as a contracting officer.

About Jenica Patterson, Ph.D.: Jenica Patterson, Ph.D is a Portfolio Lead at ARPA-H within the Project Accelerator Transition Innovation Office (PATIO) and leads the Sprint for Women's Health. Formerly Dr. Patterson served as the Director of the Technology Transfer and Transition (T3X) Division in the PATIO office, where she oversaw public-private partnerships for transition and the small business program for ARPA-H. Dr. Patterson received her Ph.D in Neuroscience at the University of Maryland, Baltimore County (UMBC) and served as a Science and Technical Advisor at the Defense Advance Research Project Agency, and a Program Director at NIH prior to joining ARPA-H.

Tune in to BioTalk for an informative discussion with Craig Gravitz and Jenica Patterson as we explore the innovative work of ARPA-H and its impact on health research and development.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

The conversation highlights the factors that contributed to the success of the top biopharma clusters, focusing on early investments in biotech, the generation of high-quality science, building networks with partners, and broadening clusters beyond anchor businesses. Alex elaborates on how these regions have sustained their scientific excellence and the long-lasting impact of pioneering efforts.

We explore the criteria used for ranking U.S. biopharma clusters, including NIH funding, venture capital funding, laboratory space, and the number of jobs. Alex provides insights into the methodologies and data sources, such as the NIH RePORT database, PitchBook, and regional life sciences groups, that underpin these rankings.

About Alex Philippidis: Alex Philippidis is the Senior Business Editor at Genetic Engineering & Biotechnology News (GEN). Specializing in biopharma business news and industry issues, Alex joined GEN in 2011 after covering research institutes at GenomeWeb and editing the BioRegion News newsletter. With over 20 years of experience in journalism, Alex has reported on various topics for newspapers and has been featured in major media outlets such as the New York Times and the BBC.

Tune in to BioTalk for an insightful discussion with Alex Philippidis as we explore the latest trends and developments in U.S. biopharma clusters, and the ongoing success of the BioHealth Capital Region.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Matt shares key findings from CBRE's recently released 'U.S. Life Sciences Talent Trends' report for 2024 (https://www.cbre.com/insights/books/us-life-sciences-talent-trends-2024), offering insights into what the life sciences sector can expect in the coming year. He discusses the national real estate market, highlighting the differences between office space and life science wet lab space, and emerging trends in the sector.

The conversation explores the strategic importance of the BioHealth Capital Region (BHCR), consistently ranked as a top market for life sciences research talent. Matt elaborates on what makes this region crucial for CBRE and the life sciences sector as a whole.

We also hear about how CBRE has contributed to the growth and development of the life sciences ecosystem in the BHCR, with Matt sharing examples of key projects and initiatives that stand out. Looking ahead, he outlines CBRE's plans for further expanding and enhancing its presence and services in the region, highlighting upcoming projects and investments.

Matt addresses the dynamic nature of the life sciences real estate market, discussing some of the biggest challenges in the BHCR and how CBRE is positioning itself to address these challenges while capitalizing on new opportunities.

About Matt Gardner: Matt Gardner leads CBRE's Advisory Life Sciences practice in the U.S., including occupier and investor leasing as well as sales. Before joining CBRE, he served as CEO and co-founder of the California Biomanufacturing Center. He has co-founded and served on the boards of multiple incubators across the U.S., including the Maryland Technology Development Center. Matt has a rich history of supporting life sciences companies and has contributed to numerous publications and NPR's Biotech Nation.

Tune in to BioTalk for an informative discussion with Matt Gardner as we explore the future of life sciences real estate and talent trends, and CBRE's pivotal role in supporting the growth of the BioHealth Capital Region.

Ambassador Hood discusses the current status of U.S.-Tunisia cooperation in scientific research and technology transfer, emphasizing these areas' critical role in Tunisia's development. He highlights the importance of scientific research, innovation, and technology transfer in Tunisia and explains how the U.S. can support and enhance these efforts.

We explore the Department of State-US funded CURES project in Tunisia, examining its goals, progress, and future objectives. Ambassador Hood elaborates on the significance of U.S. funding for projects like CURES and the broader impact on both nations. BioHealth Innovation, Inc. (BHI) is a contractor to FHI 360, supporting the CURES project to assist Tunisia in building its life science research, technology transfer, and commercialization capabilities.

The conversation also covers other key partnerships and projects that the U.S. supports in Tunisia, aimed at fostering research and technology transfer. Ambassador Hood shares insights into these collaborations and his vision for the future of U.S.-Tunisia relations in science and technology.

"The collaborative efforts between the U.S. and Tunisia in scientific research and technology transfer are crucial for advancing innovation and fostering economic growth. The programs we discuss on BioTalk are a testament to the great work happening in this field. I want to thank Ambassador Hood for joining us and sharing his invaluable insights on these important initiatives," says Rich Bendis.

About Joey R. Hood: Joey Hood was confirmed by the U.S. Senate on December 22, 2022. He has held several leadership positions in the U.S. Department of State's Bureau of Near Eastern Affairs, including Acting Assistant Secretary. His extensive diplomatic career includes assignments in Iraq, Kuwait, Saudi Arabia, Yemen, and Qatar. Prior to the Foreign Service, Mr. Hood was a Fulbright scholar in Burkina Faso and worked at a bank in Vermont. He earned a Master's degree from the Fletcher School at Tufts University and a Bachelor's degree from Dartmouth College.

Tune in to BioTalk for an insightful conversation with Ambassador Joey R. Hood as we explore the dynamics of U.S.-Tunisia cooperation in science and technology, and its potential to drive innovation and progress.

In this episode, Dr. Maron shares his professional journey, discussing his various roles at the University of Maryland and what drew him to the region. He provides a comparative analysis of the ecosystems in Boston/Harvard and Maryland/University of Maryland, highlighting the unique attributes and opportunities within each.

Dr. Maron introduces the Institute for Health Computing (IHC), explaining its creation, mission, and strategic partnerships with the University System of Maryland and Montgomery County. He outlines the significance of data science in improving health and wellness, addressing its increasing role and challenges.

We learn about the IHC's approach to bringing learning and healthcare directly to communities, illustrated by an example of their methodology: analyze, innovate, prevent, treat, and adapt. Dr. Maron discusses how the IHC aims to become an economic driver for the University System of Maryland, the state, the BioHealth Capital Region, and the nation, fostering startups, spinouts, commercialization efforts, and entrepreneurial activities.

Dr. Maron outlines the Institute's ambitious goals for the first five years and the range of services to be provided. He also details the decision to establish the IHC in Montgomery County, describing its new facilities and the county's supportive role.

Tune in to BioTalk for an informative discussion with Dr. Bradley Maron as we explore the future of precision medicine and the impactful work of the Institute for Health Computing.

In this episode, Dan shares the history and evolution of Technology Based Economic Development, discussing key initiatives in states like Ohio and Pennsylvania, and at the federal level. He highlights the importance of partnerships, detailing a compendium of state and federal cooperative technology programs that have driven progress in the field.

We explore the early years of SSTI, looking into its creation, mission, and initial goals, and how it has grown to support a nationwide network dedicated to fostering tech-based economies. Dan discusses the evolution and growth of state TBED programs, and the changing role of the federal government in supporting these initiatives through agencies like STCS, OSTP, Commerce, NIST, and EDA.

Dan also emphasizes the importance of private/public TBED partnerships, sharing insights into how these collaborations have bolstered economic growth and innovation. As he prepares to step down from his role after 28 years,and assume a part time role, Dan discusses the recruitment of a new CEO and reflects on SSTI's achievements, his legacy, and his vision for the organization's future.

Additionally, Dan talks about Rich Bendis's role as an original founding board member of SSTI, and his significant help in the early development of the organization. He also highlights the presence of several SSTI members in the BioHealth Capital Region.

Finally, Dan outlines SSTI's current initiatives and projections for the future, offering a glimpse into the ongoing efforts to support prosperity through science, technology, innovation, and entrepreneurship.

Experience an engaging discussion with Dan Berglund, a leader who has dedicated his career to advancing tech-based economic development and is now ready to embark on a new chapter.

Tune in to BioTalk to gain valuable insights from one of the most influential figures in the field and learn about the future of tech-based economic development.

Dan Berglund is the President and CEO of SSTI, a nonprofit organization dedicated to improving initiatives that support prosperity through science, technology, innovation and entrepreneurship. SSTI is the most comprehensive resource available for those involved in technology-based economic development. Leading SSTI since its inception in 1996, Mr. Berglund has helped SSTI develop a nationwide network of practitioners and policymakers dedicated to improving the economy through science, technology and innovation. SSTI works with this network to assist states and communities as they build tech-based economies, conduct research on best practices and trends in tech-based economic development, and encourage cooperation among and between state and federal programs. Prior to joining SSTI, Mr. Berglund worked as a consultant and for the Ohio Department of Development in a variety of positions, including Acting Deputy Director of the Division of Technological Innovation.

In this episode, we delve into the pivotal role of NIST as a non-regulatory agency within the Department of Commerce, highlighting its profound impact on measurement science, gene therapy, gene editing, synthetic biology, and regenerative medicine. Michael shares insights into NIST's collaborations, including local companies like MedImmune/AstraZeneca and Novavax, and the importance of partnerships with academic institutions like the University of Maryland in driving local biotech advancements.

We also explore specific technologies and standards such as gene delivery systems, the NIST Monoclonal Antibody Reference Material (NISTmAb), and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). Michael discusses the goals for future research and collaborations and reveals the next big developments we should anticipate in the biotech field.

Don't miss this engaging conversation as we uncover the innovations and initiatives at NIST that are shaping the future of biotechnology and healthcare.

Kory Bailey brings over a decade of leadership experience from both early-stage startups and big tech. He has emerged as a thought leader on equitable economic growth and a champion for Baltimore's tech ecosystem. As the CEO of UpSurge Baltimore, Kory is spearheading the vision for Baltimore to become the first Equitech hub globally, pioneering a new model for American innovation.

In this discussion, Kory unveils UpSurge Baltimore's mission: to cultivate a thriving tech ecosystem for innovators, founders, and talent by fostering culture and connectivity and mobilizing regional and national assets around Baltimore startups.

From exploring what drew him to Baltimore to discussing the evolution and unique aspects of UpSurge, Kory shares insights into the philanthropic landscape in Baltimore and initiatives like the Equitech Accelerator, Techstars, KHU, and CareFirst. He also delves into the primary challenges facing Baltimore and UpSurge's short-term goals focused on accountability, awareness, investment, and early-stage support.

Join us as we envision Baltimore's future in the next five years and the pivotal role UpSurge Baltimore plays in shaping it. Tune in now to be part of the conversation driving equitable economic growth and innovation in Baltimore's tech ecosystem.

In this episode, we explore Lance's journey from senior investment banker to non-profit leader, propelled by personal loss and a vision for change. We delve into the SouthPoleTrek4Cancer initiative, spearheading a global effort to raise awareness and funds for brain and rare cancer charities, culminating in a historic journey to the South Pole. We recognize Lance's leadership achievements, including ringing the Nasdaq bell twice as a cancer charity CEO, and his success in bringing the GBM AGILE Clinical Trial Platform from the US to Australia, accelerating breakthrough research efforts.

We also discuss Lance's strategic plans for growth and impact in the BioHealth Capital Region, driving forward the Cure Brain Cancer Foundation's mission. Additionally, we introduce the esteemed medical and scientific advisory committee steering the foundation's groundbreaking initiatives.

Join us for an insightful discussion as we uncover Lance Kawaguchi's transformative journey and the innovative strides being made in the fight against brain cancer. Tune in to BioTalk and be inspired!

Nanochon is leading the charge in the field of medical technology, reimagining the landscape of joint injury treatment. Their inventive implant not only restores damaged cartilage but also fosters fresh tissue growth. Utilizing cutting-edge 3-D printing technology and groundbreaking material, Nanochon's implant serves as both a resilient orthopedic load-bearing device and a scaffold for tissue regeneration. This advancement is poised to redefine patient recoveries, trim healthcare costs, and establish new benchmarks in cartilage rehabilitation.

In this episode, we learn about Nanochon's beginnings, the uniqueness of their technology, the individuals constituting their team, their funding strategies, and the challenges they've overcome.

Don't miss this episode as we venture into the frontier of advanced medical solutions with Nanochon. Tune in now and be part of the conversation reshaping the future of joint health.

Discover the compelling story behind Solaxa's choice to establish its roots in Montgomery County and how the BioHealth Capital Region has played a crucial role in its growth. Learn how Solaxa's team was assembled, including the inspiring success stories of Luis and Jennifer, both part of the BioHealth Innovation and Montgomery County Maryland's Executive in Residence program.

Hear how Solaxa is making a difference in the world of neurology with SLX-001, a drug showing immense promise in treating cerebellar ataxias. Dive into their innovative approach, including the development of their treatment for cerebellar ataxias.

Additionally, discover how Solaxa's pioneering efforts in this field provide hope for healing. Join us for an enlightening discussion on the future of neurology, innovative treatments, and the remarkable journey of Solaxa.

CEO & Founder Christian Walker has focused his last twenty years pursuing the commercialization of nerve injury solutions. Christian's fundraising experience spans raising money for start-ups, being a start-up venture capitalist, and securing significant non-dilutive financing through grants. At Christian's prior start-ups, Christian was directly responsible for securing $11M in venture financing. While at Toucan Capital, he served as Principal of a $140 million venture capital fund focused on early-stage investments in stem cells and regenerative medicine. At Johns Hopkins and Walter Reed, he helped secure $22.5M in non-dilutive grants.

Luis T. Gutierrez, Jr. serves as Chief Operating Officer of Solaxa while also serving as an Executive in Residence with BioHealth Innovation. In both roles, he leverages his 25+ years of expertise in helping novel medical technologies with scientific and clinical promise transition to becoming successful commercial enterprises. He previously served in executive roles with Veranex, Theralink Technologies, Aptiv Solutions, and Covance.

Chief Commercial Officer Jennifer Butler has 25 years of broad biotechnology industry experience. Her commercial roles at MedImmune, AstraZeneca, and Innate have equipped her with a deep understanding of commercial execution at large and emerging biopharma. Notably, Jen launched Innate's first commercial product in a rare oncology population. Jennifer also is also serving as an Executive in Residence with BioHealth Innovation.

Join us as we embark on an insightful discussion about the current state of AI in the BioHealth industry, diving deep into the realities and challenges of this cutting-edge technology. Dr. Klenk shares his interest in AI and the reasons behind its increasing prominence in the field. We explore the historical origins of the AI hype cycle and how we've reached the stage we're in today.

Discover tangible examples that illustrate AI's true value, benefits, and impact in BioHealth. Dr. Klenk sheds light on the underlying key technologies that power AI and the associated challenges and risks.

Looking to the future, we examine the outlook for AI in the coming months, years, and even this decade. Will the AI hype continue, or will we witness substantial breakthroughs and transformations? Dr. Klenk offers valuable insights into what organizations can and should do to ride the AI wave effectively.

Don't miss this engaging conversation with Dr. Juergen Klenk as we navigate the exciting world of AI in the BioHealth industry. Tune in now to gain a deeper understanding of AI's reality and its potential to shape the future of healthcare and research.

Join us as we explore the journey of Mobius Scientific, an early-stage biotechnology company with a transformative approach. Mobius is developing cutting-edge biologic therapies targeting the root cause of chronic diseases, starting with lipid accumulation. This innovative platform has the potential to change the lives of millions suffering from debilitating conditions.

Discover the remarkable story behind Mobius, from its scientific origins and unique name to Dr. Mehta's decision to venture into the world of entrepreneurship. We discuss the science and technology that sets Mobius apart, revealing its pivotal role in addressing age-related macular degeneration (AMD), a leading cause of blindness globally.

Meet the exceptional team and advisors that drive Mobius forward and learn how the company secured its initial funding and gained visibility through strategic contests. Dr. Mehta shares critical milestones and future goals, providing insights into the promising future of Mobius and its mission to combat chronic diseases.

Throughout the episode, we'll also explore how the BioHealth Capital Region has supported the growth and development of Mobius.

Tune in now and be part of the movement to combat chronic diseases with Dr. Nehal Mehta and Mobius Scientific.

• Meet Matt and Blackbird: Learn about Matt Tremblay's story and gain insights into Blackbird Laboratories' mission, vision, partners, and the exceptional team and advisory board guiding their endeavors.
• Investment Insights: Explore Blackbird Labs' unique investment philosophy, encompassing the stage, scale, and industries they target. Delve into their specific focus on critical science domains and gain a glimpse into the innovative projects they've already championed.
• The Baltimore and Maryland Ecosystem: Discover the pivotal role played by Baltimore and Maryland in fostering the growth of the BioHealth Capital Region. Learn about the trailblazers who inspire Blackbird Labs and their strategic efforts to support and empower the regional BioHealth community.

Don't miss this insightful episode as we discuss the promising future of BioHealth with Blackbird Laboratories leading the way. Tune in now and become an integral part of the conversation shaping the BioHealth industry's destiny.

• The origins and mission of Luminoah, driven by a deeply personal experience.
• The development of the world's first truly portable, connected tube feeding system that's set to revolutionize enteral nutrition.
• Neal's passion for leveraging technology to transform healthcare and create positive impacts on communities worldwide.

Don't miss this enlightening conversation as we journey into the heart of MedTech innovation with Neal Piper. Tune in now and be part of the conversation that's shaping the future of healthcare for enteral nutrition patients.

In this enlightening episode, Dr. Nijhara, a forward-thinking leader driven by her passion for advancing scientific innovation, delves into the funding mechanisms that Maryland employs to support research and development at all stages and fosters collaboration and innovation.

Discover MSCRF's pivotal role in reshaping healthcare through stem cell research. Explore funding opportunities, real-world project examples, and success stories that highlight the profound impact of this research on healthcare and scientific advancements.

Don't miss this captivating conversation on how MSCRF is shaping the future of scientific innovation in Maryland and beyond. Tune in now to discover more about MSCRF.

• What is Horizon Therapeutics' mission, and what are Dr. Podrebarac's primary responsibilities in this quest for life-changing medicines?
• How has Dr. Podrebarac's background as a rheumatologist influenced her belief in the importance of the patient's perspective in drug development?
• Discover Horizon's impressive journey in clinical development, with a sharp focus on autoimmune diseases.
• Dive into Horizon's global presence and the crucial role of its Maryland operations.
• What are the clinical goals that will shape the future of autoimmune medicine?

Don't miss this enlightening conversation that delves into the nexus of science, patient advocacy, and innovation. Tune in now and become part of the future where patients' voices are not just heard but lead the way in shaping a brighter tomorrow. Available on all major podcasting platforms. Theresa Podrebarac, M.D., M.Sc., is a physician scientist with extensive development expertise in the biotech industry. At Horizon Therapeutics, Dr. Podrebarac leads the clinical development function dedicated to bringing medicines for rare, autoimmune and severe inflammatory diseases to patients. Prior to Horizon, Dr. Podrebarac served as chief medical officer at two biotech companies focusing on rare diseases. She was also vice president, immunology clinical development at AbbVie where she helped develop approved therapies for psoriasis and rheumatoid arthritis. At Biogen, she championed the development of tools and techniques for early clinical proof of concept in diseases including scleroderma and lupus skin disease. Dr. Podrebarac holds a master of science in immunology from the University of Ottawa and a medical doctorate degree from Western University. She completed a postdoctoral fellowship in immunology at Harvard University.

Discover the upcoming NAAS/AJAS STEM EDUCATION CONFERENCE/FUNDRAISER on September 16th and its impact on inspiring the next generation of innovators. Learn about AJAS's life science support programs that encourage young talents to pursue careers in STEM.

Dr. Staveley shares insights into STEM education in the BioHealth Capital Region and her personal goals for nurturing young scientists. Join us to uncover the pivotal role of mentorship in shaping the future of STEM. Listen now on major podcasting platforms.

Bill offers a compelling update in this installment since his previous appearance on BioTalk. Learn about the intriguing journey that led Vaccitech, a clinical-stage T cell immunotherapy and vaccine company, to select Montgomery County, MD, within the thriving BioHealth Capital Region, for its new site. Delve into the intricacies of their pioneering platform, which harnesses the power of immunotherapy to elicit robust T cell responses and antibodies against infectious agents and tumors.

Get an insider's perspective as Bill provides clinical updates on their groundbreaking work, discussing major milestones in critical areas like HBV, HPV, PCA, and VTB, among others. Explore Vaccitech's path forward as Bill sheds light on their next significant milestones and strategic plans to expand their presence within the United States.

Don't miss this exclusive conversation with Bill Enright as he shares insights into the dynamic world of immunotherapy and Vaccitech's mission to transform the disease treatment and prevention landscape.

In this episode of BioTalk, host Rich Bendis chats with Brad L. Stewart, SVP of Economic Development for Montgomery County Economic Development Corporation (MCEDC). Brad's multifaceted career spans from being a Chief Executive Officer to leading expert teams in strategy and innovation, plus economic development specialists in Montgomery County.

Together, they delve into the MCEDC Life Science support programs, the remarkable evolution of the region over the last 20 years, Brad's new role as Chair of MTC, and the shared values and collaboration in the region. They also celebrate Brad's achievements and discuss the current state of the Life science industry, especially in MOCO and BHCR.

Join this engaging conversation to uncover the strategies and insights that have shaped Montgomery County's economy and the life sciences field. Learn from Brad's leadership and his ability to thrive on complex strategic opportunities. Tune in to this episode of BioTalk to explore the innovative and collaborative spirit that's driving growth and success in the industry.

The fireside chat includes a discussion on Dr. Fauci's personal background and interest in healthcare issues, his role at NIAID and serving the Administration, the importance of NIH to the Country and the BioHealth Capital Region and career opportunities at NIAID and NIH. They also discuss the Covid 19 Pandemic and recommendations to address proactive measures to reduce the impact of potential future pandemics.

On the heels of Silicon Valley's branding as one of the world's largest tech hubs, the BioHealth Capital Region aims to brand the DMV region as one of the most prominent BioHealth clusters in the Mid-Atlantic. BioHealth Innovation, Inc. was founded 11 years ago in an effort to drive ideas from labs into markets through innovation-driven economic development organizations and initiatives.

Galvin and Bendis discuss the abundance of opportunities for growth within the region as it is home to a wide variety of research institutions, top scientists, and annual grants. Additionally, they discuss how BioHealth Innovation, Inc. cultivates success for companies within the competitive region.

For more information on BioHealth Innovation, go to:

biohealthinnovation.org

If you like this video, please subscribe to our channel: youtube.com/channel/UCqRz...

Also, please leave us a comment to let us know how you liked it as well as any additional subjects you'd like us to cover.

About AGT:

American Gene Technologies (AGT) is a clinical-stage, gene and cell therapy company in Rockville, Maryland with a proprietary gene-delivery platform for rapid drug development of infectious diseases, cancers, and inherited disorders. AGT's mission is to transform people's lives through genetic medicines that rid the body of disease.